Abstract: The present invention related to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy) heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppression of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anticancer, obesity and a suppressing agent for aging and stress.

Abstract: This invention relates to lithospermate B (‘LAB’ hereinafter) that inhibits proliferation and migration of vascular smooth muscle cells (‘VSMC’ hereinafter). More specifically, this invention relates to a pharmaceutical composition comprising LAB isolated from Salviae miltiorrhiza as an active ingredient for treating atherosclerosis.

Abstract: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy) heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anti-cancer, obesity and a suppressing agent for aging and stress.

Abstract: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy)heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anti-cancer, obesity and a suppressing agent for aging and stress.

Abstract: This invention relates to lithospermate B (‘LAB’ hereinafter) that inhibits proliferation and migration of vascular smooth muscle cells (‘VSMC’ hereinafter). More specifically, this invention relates to a pharmaceutical composition comprising LAB isolated from Salviae miltiorrhiza as an active ingredient for treating atherosclerosis.

Abstract: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy)heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer system in vivo, and anti-cancer, obesity and a suppressing agent for aging and stress.

Abstract: Diabetic nephropathy and microalbuminuria are treated with the herb Salviae Miltiorrhizae Radix. In one embodiment, the method includes boiling the herb to form an aqueous extract. The aqueous extract is administered to the diabetic individual to treat diabetic nephropathy or to an individual exhibiting microalbuminuria. Alternatively the method can include administering a salt of lithospermic acid extracted from the herb. The method can include determining the level of protein in urine before, during and/or after administering the aqueous extract or a salt of lithospermic acid.

Abstract: Diabetic nephropathy and microalbuminuria are treated with the herb Salviae Miltiorrhizae Radix. In one embodiment, the method includes boiling the herb to form an aqueous extract. The aqueous extract is administered to the diabetic individual to treat diabetic nepliropathy or to an individual exhibiting microalbuminuria. Alternatively the method can include administering a salt of lithospermic acid extracted from the herb. The method can include determining the level of protein in urine before, during and/or after administering the aqueous extract or a salt of lithospermic acid.

Abstract: Diabetic nephropathy and microalbuminuria are treated with the herb Salviae Miltiorrhizae Radix. In one embodiment, the method includes boiling the herb to form an aqueous extract. The aqueous extract is administered to the diabetic individual to treat diabetic nephropathy or to an individual exhibiting microalbuminuria. Alternatively the method can include administering a salt of lithospermic acid extracted from the herb. The method can include determining the level of protein in urine before, during and/or after administering the aqueous extract or a salt of lithospermic acid.

Abstract: This invention is a new method for preparing compounds useful as antimalarial agents having the formula; ##STR1## wherein R is hydrogen, a linear, branched or cyclo lower alkyl group having 1 to 8 carbon atoms; aminoalkyl; branched aminoalkyl; hydroxyalkyl: alkylcarboxylate or alkylbenzoate groups having 1 to 5 carbon atoms in the alkyl chains; aryl; alkoxy-substituted aryl; heteroaryl; and pyridinium groups. The method comprises treating artemisinic acid with a methylating agent followed by a stereoselective reduction of the methylated compound, subjecting the reduced compound to a Grignard addition followed by chiral photoxidation with subsequent treatment with a cyclization agent.

Abstract: This invention provides a new antimalarial compound, deoxoartemisinin, having the formula: ##STR1## Antimalarial compositions consisting essentially of the compound in admixture with a non-toxic, pharmaceutically-acceptable carrier. A method for treating malaria comprising administering a therapeutically effective concentration of the compound, preferably in admixture with a non-toxic, pharmaceutically-acceptable carrier. A method of preparing the deoxoartemisinin.

Abstract: This invention provides a new antimalarial compound, deoxoartemisinin, having the formula: ##STR1## Antimalarial compositions consisting essentially of the compound in admixture with a non-toxic, pharmaceutically-acceptable carrier. A method for treating malaria comprising administering a therapeutically effective concentration of the compound, preferably in admixture with a non-toxic, pharamceutically-acceptable carrier. A method of preparing the doxoartemisinin.